Shares of Alembic Pharmaceuticals, based in Gujarat, India, fell over 9% to ₹710.70 after the company reported disappointing Q4FY26 results. Despite a 29% year-on-year increase in net profit to ₹202 crore, weak margins and lower-than-expected revenue led to a decline in stock performance, prompting analysts to adjust earnings forecasts.

• 01Alembic Pharma's revenue for Q4FY26 rose 4.4% year-on-year to ₹1,848 crore, but fell short of analyst expectations.
• 02The company's earnings before interest, tax, depreciation, and amortisation (Ebitda) dropped 16.2% to ₹228 crore, resulting in a narrowed Ebitda margin of 12.3%.
• 03Motilal Oswal Financial Services noted that Alembic's revenue, Ebitda, and profit after tax (PAT) were 2%, 29%, and 43% below estimates, respectively.
• 04The company launched six products in the US market during the quarter, contributing to an 11% growth in international business.
• 05Analysts have lowered their earnings estimates for FY27 and FY28 by 12% and 6%, respectively, citing slower growth in domestic segments and increased R&D costs.

The decline in Alembic Pharma's stock price may affect investor confidence and could impact future funding for growth initiatives.